Simcere Pharmaceutical Group Limited
2096
Classifica tra le azioni
#4480
Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the... Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including distributors, pharmacy chains, and fellow drug manufacturers within China. The company strategically focuses on a diverse range of therapeutic areas, notably oncology, central nervous system conditions, autoimmune diseases, anti-infective treatments, and cardiovascular health, among others. Its extensive product portfolio features key medications such as Sanbexin (an edaravone and dexborneol concentrated solution for injection), Endostar (a recombinant human endostatin injection), ENWEIDA (an envafolimab injection), Softan (rosuvastatin calcium tablets), ZAILIN (amoxicillin in granules, dispersible tablets, or capsules), Iremod (iguratimod tablets), Antine (diclofenac sodium sustained-release capsules or gel), and Orencia (an abatacept injection). Additionally, Simcere offers specialized promotional services for pharmaceutical goods. Demonstrating its commitment to innovation, the group has established a strategic regional licensing collaboration with Vivoryon Therapeutics N.V. This partnership aims to develop and commercialize novel therapies for Alzheimer's disease by targeting the neurotoxic amyloid protein N3pE (pGlu-Aß). Established in 1995, Simcere Pharmaceutical Group Limited is headquartered in Nanjing, China.
Prezzo delle azioni
$1.32
Capitalizzazione di mercato
$3.40B
Variazione (1 giorno)
-4.51%
Variazione (1 anno)
-19.88%
Paese
CN
Scambia Simcere Pharmaceutical Group Limited (2096)
Categoria
Healthcare
Rapporto P/B per Simcere Pharmaceutical Group Limited (2096)
Rapporto P/B al October 2026 TTM: 2.39
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Simcere Pharmaceutical Group Limited, il rapporto P/B attuale (TTM) è 2.39. Alla fine del 2024, era pari a 2.39.
Storico del rapporto P/B per Simcere Pharmaceutical Group Limited da 2012 a 2026
Rapporto P/B alla fine di ogni anno
| Anno | Rapporto P/B | Cambia |
|---|---|---|
| 2026 (TTM) | 2.39 | -15.80% |
| 2025 | 2.84 | 19.18% |
| 2024 | 2.39 | 9.48% |
| 2023 | 2.18 | -42.05% |
| 2022 | 3.76 | 26.70% |
| 2021 | 2.97 | -19.91% |
| 2020 | 3.70 | -78.54% |
| 2019 | 17.26 | 7.61% |
| 2018 | 16.04 | 19.86% |
| 2017 | 13.38 | 2,739.85% |
| 2012 | 0.47 | 0.00% |
Rapporto P/B per aziende simili o concorrenti
| Azienda | Rapporto P/B | Differenza del rapporto P/B | Il paese |
|---|---|---|---|
| 6.251 | 161.39% |
US
|
|
| 13.2547 | 454.27% |
US
|
|
| 4.4521 | 86.17% |
AU
|
|
| 6.3632 | 166.09% |
NL
|
|
| 3.2932 | 37.71% |
BE
|
